Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. (KYMR) Stock Overview
Explore Kymera Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
7B
P/E Ratio
-23.14
EPS (TTM)
$-3.69
ROE
-0.29%
KYMR Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Kymera Therapeutics, Inc. (KYMR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 58.58, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $80.16.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -23.14 and a market capitalization of 7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.